TABLE 1.
Main drugs and events. Ranking of reactions (HLTs, High Level Terms), Active Ingredients, and Primary Suspect (PS) Active Ingredients in COVID-19 patients.
| Rank | Events (HLTs) | N° reports (%) | Active ingredients | N° reports (%) | PS active ingredients | N° reports (%) |
|---|---|---|---|---|---|---|
| 1 | Renal failure and impairment | 730 (10.3%) | Remdesivir | 3,342 (47.2%) | Remdesivir | 2,744 (38.8%) |
| 2 | Coronavirus infections | 534 (7.5%) | Hydroxy chloroquine | 2,717 (38.4%) | Hydroxy chloroquine | 939 (13.3%) |
| 3 | Hepatocellular damage and hepatitis NEC | 388 (5.4%) | Azithromycin | 2,162 (30.5%) | Azithromycin | 702 (9.9%) |
| 4 | Ventricular arrhythmias and cardiac arrest | 365 (5.2%) | Enoxaparin | 1,420 (20.0%) | Tocilizumab | 584 (8.3%) |
| 5 | Respiratory failures (excluded neonatal) | 358 (5.1%) | Tocilizumab | 1,260 (17.8%) | Lopinavir | 364 (5.1%) |
| 6 | Rate and rhythm disorders NEC | 277 (3.9%) | Ceftriaxone | 1,193 (16.9%) | Ritonavir | 335 (4.7%) |
| 7 | Breathing abnormalities | 230 (3.3%) | Ritonavir | 1,186 (16.8%) | Sarilumab | 151 (2.1%) |
| 8 | Sepsis, bacteremia, viraemia, and fungaemia NEC | 226 (3.2%) | Lopinavir | 1,160 (16.4%) | Ethanol | 123 (1.7%) |
| 9 | Pulmonary oedemas | 192 (2.7%) | Paracetamol | 914 (12.9%) | Methyl prednisolone | 100 (1.4%) |
| 10 | Nausea and vomiting symptoms | 183 (2.6%) | Dexamethasone | 849 (12.0%) | Oseltamivir | 91 (1.2%) |